Tumor Biology and Microenvironment Program Themes

Theme 1: To identify molecular, cellular determinants of malignancy (metastasis drivers)

Our investigators study key signaling pathways involved in tumorigenicity, tumor cell phenotypical plasticity, and tumor cell drug response (metastasis operatives).

Theme 1 Accomplishments 

Theme 2: To identify and exploit the underlying mechanisms of tumor metastasis (operatives)

Our investigators study the function and underlying mechanisms such as the extracellular proteolysis/signaling network that enable tumor cells to adapt to and eventually overcome the varying microenvironments.

Theme 2 Accomplishments 

Theme 3: To identify and exploit stromal reactivity and host immunity to tumor progression (host response to metastatic tumors)

Our investigators study the interaction of tumor cells with mesenchyme and innate immune cells. We also identify, evaluate and utilize adaptive cellular and humoral immune responses to develop immunotherapy approaches.

Theme 3 Accomplishments 

The Latest From Karmanos Cancer Institute

News

Karmanos Cancer Institute Receives the 2026 Women’s Choice Award® as One of America’s Best Hospitals for Cancer Care

Karmanos Cancer Hospital, part of the Barbara Ann Karmanos Cancer Institute , has been named one of America’s Best Hospitals for Cancer Care in 20...

Read More

Your Family History Matters: What Genetic Counseling Can Reveal

Your genes play a meaningful role in your health—shaping everything from your physical features to your risk for certain medical conditions, inclu...

Read More

IN THE NEWS: Early Detection is Key for Breast Cancer Diagnosis

WDIV Catching breast cancer early, before it spreads, gives patients better treatment options and outcomes. Hadeel Assad, M.D. , medical oncologis...

Read More
News

WSGW | Risks of Pancreatic Cancer

Listen Now

WWJ | Karmanos Psychologist on Emotional Impact of Breast Cancer Diagnosis

Listen Now

WWJ | ‘Houses with Roofs Caved In’: Karmanos Surgeon Explains Stage 0 Breast Cancer (DCIS)

Listen Now